Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. II. Deletion of effector cells by fas-fas ligand apoptosis

Journal of Immunology

Volumn 173, Issue 11, 2004, Pages 6660-6666

  Reich Zeliger, Shlomit ^a   Gan, Judith ^a   Bachar Lustig, Esther ^a   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; LIPOCORTIN 5; OKT 8; PROTEIN BCL 2;

ALLELE; ANIMAL CELL; ANTIBODY AFFINITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL ACTIVITY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; GENE EXPRESSION; IMMUNOLOGICAL TOLERANCE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; T LYMPHOCYTE; TRANSGENE; TRANSGENIC MOUSE; UPREGULATION;

EID: 9144242988     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.11.6660     Document Type: Article

References (30)

1. Sambhara, S. R., and R. G. Miller. 1991. Programmed cell death of T cells signaled by the T cell receptor and the α3 domain of class I MHC. Science 252:1424.
2. + cells whose class I MHC can bind the peptide. J. Immunol. 152:1103.
3. Asiedu, C., Y. Meng, W. Wang, Z. Huang, J. L. Contreras, J. F. George, and J. M. Thomas. 1999. Immunoregulatory role of CD8α in the veto effect. Transplantation 67:372.
4. + CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 13:507.
5. + T cells in vivo. J. Immunol. 163:2561.
6. + CTL by in vivo retrovirus-infected cells. J. Immunol. 168:2751.
7. George, J. F., and J. M. Thomas. 1999. The molecular mechanisms of veto mediated regulation of alloresponsiveness. J. Mol. Med. 77:519.
8. + antiviral T cells by viral antigen-positive veto cells. J. Virol. 73:3826.
9. Anel, A., M. Buferne, C. Boyer, A. M. Schmitt-Verhulst, and P. Golstein. 1994. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur. J. Immunol. 24:2469.
10. Kataoka, T., M. Schroter, M. Hahne, P. Schneider, M. Irmler, M. Thome, C. J. Froelich, and J. Tschopp. 1998. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J. Immunol. 161:3936.
11. Schroter, M., B. Lowin, C. Borner, and J. Tschopp. 1995. Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur. J. Immunol. 25:3509.
12. Lee, R. K., J. Spielman, and E. R. Podack. 1996. Bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis. Int. Immunol. 8:991.
13. Tamm, I., Y. Wang, E. Sausville, D. A. Scudiero, N. Vigna, T. Oltersdorf, and J. C. Reed. 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315.
14. Van Oostveldt, K., H. Dosogne, C. Burvenich, M. J. Paape, V. Brochez, and E. Van den Eeckhout. 1999. Flow cytometric procedure to detect apoptosis of bovine polymorphonuclear leukocytes in blood. Vet. Immunol. Immunopathol. 70:125.
15. Schutte, B., R. Nuydens, H. Geerts, and F. Ramaekers. 1998. Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J. Neurosci. Methods 86:63.
16. Span, L. F., A. H. Pennings, G. Vierwinden, J. B. Boezeman, R. A. Raymakers, and T. de Witte. 2002. The dynamic process of apoptosis analyzed by flow cytometry using annexin-V/propidium iodide and a modified in situ end labeling technique. Cytometry 47:24.
17. Strasser, A., A. W. Harris, D. C. Huang, P. H. Krammer, and S. Cory. 1995. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 14:6136.
18. Villunger, A., L. A. O'Reilly, N. Holler, J. Adams, and A. Strasser. 2000. Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: regulators of distinct cell death and survival pathways in granulocytes. J. Exp. Med. 192:647.
19. L. Proc. Natl. Acad. Sci. USA 96:14871.
20. Muppidi, J. R., and R. M. Siegel. 2004. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat. Immunol. 5:182.
21. Scheel-Toellner, D., K. Wang, R. Singh, S. Majeed, K. Raza, S. J. Curnow, M. Salmon, and J. M. Lord. 2002. The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem. Biophys. Res. Commun. 297:876.
22. Gajate, C., and F. Mollinedo. 2001. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98:3860.
23. 1 T cells. Blood 94:3212.
24. Rachamim, N., J. Gan, H. Segall, R. Krauthgamer, H. Marcus, A. Berrebi, M. Martelli, and Y. Reisner. 1998. Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 65:1386.
25. Saffran, D. C., M. F. Parsons, and S. K. Singhal. 1991. Separation of allostimulatory and natural suppressor/stem cell functions of murine bone marrow: implications for bone marrow transplantation. Transplantation 52:680.
26. Thomas, J. M., F. M. Carver, P. R. Cunningham, L. C. Olson, and F. T. Thomas. 1991. Kidney allograft tolerance in primates without chronic immunosuppression: the role of veto cells. Transplantation 51:198.
27. Thomas, J. M., F. M. Carver, J. Kasten-Jolly, C. E. Haisch, L. M. Rebellato, U. Gross, S. J. Vore, and F. T. Thomas. 1994. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation 57:101.
28. + cells. Immunology 94:101.
29. Chrobak, P., and R. E. Gress. 2001. Veto activity of activated bone marrow does not require perform and Fas ligand. Cell. Immunol. 208:80.
30. Nakamura, H., and R. E. Gress. 1990. Interleukin 2 enhancement of veto suppressor cell function in T-cell-depleted bone marrow in vitro and in vivo. Transplantation 49:931.